Untitled

Ling, Pei-Ra; Sheikh, Mohammed; Boyce, Patricia J.; Keane-Ellison, Mary; Thibault, Ann; Burke, Patricia A.; Freedman, Steven D.; Bistrian, Bruce R.

doi:10.1023/a:1010772922341

Cited by 27 publications

(1 citation statement)

References 17 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Most of these stones consist of calcium bilirubinate. The formation of gallbladder stones is favored by altered enterohepatic circulation[ 14 ], gallbladder hypomobility[ 15 ], and the reduced secretion of cholecystokinin after meals[ 16 ]. The formation of calcium oxalate kidney stones is also common, especially in patients with SBS and colon in continuity[ 17 ].…”

Section: Introductionmentioning

confidence: 99%

Glucagon-like peptide-2 analogues for Crohn’s disease patients with short bowel syndrome and intestinal failure

Pizzoferrato¹,

Puca²,

Ennas³

et al. 2022

World J Gastroenterol

View full text Add to dashboard Cite

Short bowel syndrome (SBS) with intestinal failure (IF) is a rare but severe complication of Crohn’s disease (CD), which is the most frequent benign condition that leads to SBS after repeated surgical resections, even in the era of biologics and small molecules. Glucagon-like peptide-2 analogues have been deeply studied recently for the treatment of SBS-IF. These drugs have a significant intestinotrophic effect and the potential to reduce the chronic dependence of SBS-IF patients on parenteral support or nutrition. Teduglutide has been approved for the treatment of SBS-IF, and apraglutide is currently in clinical development. The use of these drugs was examined with a focus on their use in CD patients.

show abstract

Section: Introductionmentioning

confidence: 99%

Glucagon-like peptide-2 analogues for Crohn’s disease patients with short bowel syndrome and intestinal failure

Pizzoferrato¹,

Puca²,

Ennas³

et al. 2022

World J Gastroenterol

View full text Add to dashboard Cite

show abstract

Irreversible Intestinal Failure

Goulet,

Ruemmele,

Lacaille

et al. 2004

J. pediatr. gastroenterol. nutr.

View full text Add to dashboard Cite

Intestinal failure (IF) can be defined as the reduction of functional gut mass below the minimal amount necessary for digestion and absorption adequate to satisfy the nutrient and fluid requirements for maintenance in adults or growth in children. In developed countries, IF mainly includes individuals with the congenital or early onset of conditions requiring protracted or indefinite parenteral nutrition (PN). Short bowel syndrome was the first commonly recognized cause of protracted IF. The normal physiologic process of intestinal adaptation after extensive resection usually allows for recovery of sufficient intestinal function within weeks to months. During this time, patients can be sustained on parenteral nutrition. Only a few children have permanent intestinal insufficiency and life‐long dependency on PN. Non‐transplant surgery including small bowel tapering and lengthening may allow weaning from PN in some cases. Hormonal therapy with recombinant human growth hormone has produced poor results while therapy with glucagon‐like peptide‐2 holds promise. Congenital diseases of enterocyte development such as microvillus inclusion disease or intestinal epithelial dysplasia cause permanent IF for which no curative medical treatment is currently available. Severe and extensive motility disorders such as total or subtotal intestinal aganglionosis (long segment Hirschsprung disease) or chronic intestinal pseudo‐obstruction syndrome may also cause permanent IF. PN and home‐PN remain are the mainstays of therapy regardless of the cause of IF. Some patients develop complications while receiving long‐term PN for IF especially catheter related complications (thrombosis, sepsis) and liver disease. These patients may be candidates for intestinal transplantation. This review discusses the causes of irreversible IF and emphasizes the specific medico‐surgical strategies for prevention and treatment of these conditions at several stages of IF.

show abstract

Gallstones in Intestinal Failure

Nightingale,

Soop

2023

Intestinal Failure

View full text Add to dashboard Cite

Untitled

Cited by 27 publications

References 17 publications

Glucagon-like peptide-2 analogues for Crohn’s disease patients with short bowel syndrome and intestinal failure

Glucagon-like peptide-2 analogues for Crohn’s disease patients with short bowel syndrome and intestinal failure

Irreversible Intestinal Failure

Gallstones in Intestinal Failure

Contact Info

Product

Resources

About